Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - Nobelpharma/SBI Pharmaceuticals

Next Previous
Drug Profile

Aminolevulinic acid - Nobelpharma/SBI Pharmaceuticals

Alternative Names: 5-ALA - Nobelpharma; Alabel; Alaglio; NPC-07; PD G 506 A

Latest Information Update: 28 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SBI Pharmaceuticals Co Ltd
  • Developer Chugai Pharmaceutical; Kyoto University; Nobelpharma; SBI Pharmaceuticals Co Ltd
  • Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioma
  • Registered Bladder cancer
  • Phase III Breast cancer
  • Phase II Biliary cancer; Pancreatic cancer; Solid tumours
  • No development reported Anaemia; Atherosclerosis; Cervical intraepithelial neoplasia; Cholangiocarcinoma; Cognition disorders

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for preclinical development in Atherosclerosis in Japan
  • 28 May 2021 No recent reports of development identified for clinical-Phase-Unknown development in Cervical-intraepithelial-neoplasia(Diagnosis, In adults) in Japan (PO)
  • 07 May 2021 Phase-III clinical trials in Breast cancer (Diagnosis, In adults, In the elderly) in Canada, USA (PO) (NCT04815083)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top